Arecoline (/əˈrɛkəliːn/) is a nicotinic acid-based mild parasympathomimetic stimulant alkaloid found in the areca nut, the fruit of the areca palm (Areca catechu).[2] It is an odourless oily liquid. It can bring a sense of enhanced alertness and energy along with mild feelings of euphoria and relaxation. The psychoactive effects are comparable to that of nicotine.
Arecoline is a base, and its conjugate acid has a pKa ~ 6.8.[3]
Arecoline is volatile in steam, miscible with most organic solvents and water, but extractable from water by ether in presence of dissolved salts. Being basic, arecoline forms salts with acids. The salts are crystalline, but usually deliquescent: the hydrochloride, arecoline•HCl, forms needles, m.p. 158 °C;[3] the hydrobromide, arecoline•HBr, forms slender prisms, mp. 177–179 °C from hot methanol; the aurichloride, arecoline•HAuCl4, is an oil, but the platinichloride, arecoline2•H2PtCl6, mp. 176 °C, crystallizes from water in orange-red rhombohedrons. The methiodide forms glancing prisms, mp. 173-174 °C.
Arecoline promotes excitation and decreases sleeping time. It also enhances learning and memory. Intraperitoneal administration of arecoline decreases locomotor activity dose-dependently. Arecoline reversed scopolamine induced memory loss. It could also decrease symptoms of depression and schizophrenia [8]
AN (Areca Nut) is a vasodilator mainly due to the presence of arecoline. It also has anti-thrombosis and anti-atherogenic effects by increasing plasma nitric oxide, eNos, and mRNA expression and decreasing IL-8 along with other downregulations.[8]
It increases the level of testosterone by stimulating Leydig's cells as well as levels of FSH and LH.[9][10] It also activates HPA axis and stimulates CRH release. It prevents the dysfunction of B cells of the pancreas from high fructose intake.[8]
Arecoline has the ability to stimulate the digestive system through the activation of muscarinic receptors. Areca nut water extract could increase the contractions of gastric smooth muscle and muscle strips of the duodenum, ileum, and colon significantly. This activity could be caused by arecoline.[8]
Arecoline is metabolized by both kidneys and liver.[11] Currently, 11 metabolites of arecoline are documented among which N-methylnipecotic acid was found to be a major metabolite of both arecoline and arecaidine.[12] Lime is said to hydrolyse almost all arecoline to arecaidine, a GABA reuptake inhibitor.[13] Arecaidine is also formed during liver metabolism of arecoline in rats.[12]
Owing to its muscarinic and nicotinic agonist properties, arecoline has shown improvement in the learning ability of healthy volunteers. Since one of the hallmarks of Alzheimer's disease is a cognitive decline, arecoline was suggested as a treatment to slow down this process and arecoline administered intravenously did indeed show modest verbal and spatial memory improvement in Alzheimer's patients, though due to arecoline's possible carcinogenic properties,[14] it is not the first drug of choice for this degenerative disease.[15] In many Asian cultures, the areca nut is chewed along with betel leaf to obtain a stimulating effect.[16]
Arecoline has also been used medicinally as an antihelmintic (a drug against parasitic worms).[17]
Arecoline has also been shown to increase testosterone in rats, in low doses.
[9]
LD50: 100 mg/kg, administered subcutaneously in mouse.[3] Also, the minimum lethal dose (MLD) values of arecoline in mice, dog and horse is 100 mg/kg, 5 mg/kg and 1.4 mg/kg respectively. It causes Oral Submucous Fibrosis by stimulating collagen, interleukin 6, keratinocyte growth factor-1, IGF-1, cystatin C, tissue inhibitor of matrix metalloproteinases in the mouth.
Current science is confident that areca nut chewing is carcinogenic. Research suggests this is probably at least partly because of arecoline itself, although it could also be from the other constituents of the nut as well, some of which are precursors to nitrosamines that form in the mouth during chewing. Section 5.5 Evaluation on page 238 of IARC Monograph 85-6 states the following:[18]
[...]
There is sufficient evidence in humans for the carcinogenicity of betel quid without tobacco. Betel quid without tobacco causes oral cancer.
There is sufficient evidence in experimental animals for the carcinogenicity of betel quid without tobacco.
There is sufficient evidence in experimental animals for the carcinogenicity of betel quid with tobacco.
There is sufficient evidence in experimental animals for the carcinogenicity of areca nut.
There is sufficient evidence in experimental animals for the carcinogenicity of areca nut with tobacco.
There is limited evidence in experimental animals for the carcinogenicity of arecoline.
There is inadequate evidence in experimental animals for the carcinogenicity of arecaidine.
[...]
Toxicity of arecoline can be partially mitigated by vitamins C and E. [19]
Fischer esterification of nicotinic acid (niacin) (1) gives methyl nicotinate [93-60-7] (2). Alkylation with methyl iodide then gives 3-methoxycarbonyl-1-methylpyridinium iodide (3). Hydride reduction with an agent such as potassium borohydride thus gives the tetrahydropyridine (4). Salt formation with HBr completes the synthesis (5).
A double Mannich reaction between methylamine (1), acetaldehyde (2) and formaldehyde (3) in the presence of hydroxylamine hydrochloride is supposed to have delivered 1-methyl-1,2,5,6-tetrahydropyridine-3-carbaldehyde oxime hydrochloride Fb: [139886-54-7] (4) as the product. Dehydration of the aldoxime to the nitrile occurs upon treatment with acetic anhydride giving 3-cyano-1-methyl-1,2,5,6-tetrahydropyridine [5657-66-9] (5). FGI of the nitrile to the methyl carboxylate ester then occurs upon acid catalyzed treatment with methanol, and then conversion to the HBr salt completes the synthesis.
^ abcWindholz M (1983). The Merck index : an encyclopedia of chemicals, drugs, and biologicals (10th ed.). Rahway, N.J., U.S.A.: Merck & Co. p. 113. ISBN978-0-911910-27-8.
^Fisher SK, Snider RM (July 1987). "Differential receptor occupancy requirements for muscarinic cholinergic stimulation of inositol lipid hydrolysis in brain and in neuroblastomas". Molecular Pharmacology. 32 (1): 81–90. PMID3600615.
^Mei L, Lai J, Yamamura HI, Roeske WR (February 1991). "Pharmacologic comparison of selected agonists for the M1 muscarinic receptor in transfected murine fibroblast cells (B82)". The Journal of Pharmacology and Experimental Therapeutics. 256 (2): 689–94. PMID1704434.
^Yen CY, Lin MH, Liu SY, Chiang WF, Hsieh WF, Cheng YC, et al. (May 2011). "Arecoline-mediated inhibition of AMP-activated protein kinase through reactive oxygen species is required for apoptosis induction". Oral Oncology. 47 (5): 345–351. doi:10.1016/j.oraloncology.2011.02.014. PMID21440488.
^ abWang SW, Hwang GS, Chen TJ, Wang PS (August 2008). "Effects of arecoline on testosterone release in rats". American Journal of Physiology. Endocrinology and Metabolism. 295 (2): E497–E504. doi:10.1152/ajpendo.00045.2008. PMID18559981.
^Cox S, Ullah M, Zoellner H (January 2016). "Oral and systemic health effects of compulsive areca nut use.". In Preedy VR (ed.). Neuropathology of Drug Addictions and Substance Misuse; Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions. Academic Press. pp. 785–793. doi:10.1016/B978-0-12-800634-4.00078-0. ISBN978-0-12-800634-4. Animal models demonstrate that the primary sites for metabolism of arecoline are the liver (Giri et al., 2006; Nery, 1971) and kidneys (IARC, 2004).
^Saikia JR, Schneeweiss FH, Sharan RN (May 1999). "Arecoline-induced changes of poly-ADP-ribosylation of cellular proteins and its influence on chromatin organization". Cancer Letters. 139 (1): 59–65. doi:10.1016/S0304-3835(99)00008-7. PMID10408909.
^Christie JE, Shering A, Ferguson J, Glen AI (January 1981). "Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia". The British Journal of Psychiatry. 138 (1): 46–50. doi:10.1192/bjp.138.1.46. PMID7023592. S2CID24009415.
^Yusuf H, Yong SL (July 2002). "Oral submucous fibrosis in a 12-year-old Bangladeshi boy: a case report and review of literature". International Journal of Paediatric Dentistry. 12 (4): 271–276. doi:10.1046/j.1365-263X.2002.00373.x. PMID12121538.
^Kozello, I. A.; Gasheva, A. Ya.; Khmelevskii, V. I. (1976). "Improvement of the synthesis of arecoline from nicotinic acid". Pharmaceutical Chemistry Journal. 10 (11): 1515–1516. doi:10.1007/BF00760390.
^K. S. Keshave Murthy, Allan W. Rey, Dan S. Matu, U.S. patent 6,132,286 (2000 to Brantford Chemicals Inc.).
^Jean-Daniel Brion, et al. U.S. patent 20,090,258,883 (2009 to Centre National de la Recherche Scientifique CNRS, Laboratoires Servier, Universite Paris Sud (Paris 11)).
^Volgin, A. D., Bashirzade, A., Amstislavskaya, T. G., Yakovlev, O. A., Demin, K. A., Ho, Y.-J., Wang, D., Shevyrin, V. A., Yan, D., Tang, Z., Wang, J., Wang, M., Alpyshov, E. T., Serikuly, N., Wappler-Guzzetta, E. A., Lakstygal, A. M., Kalueff, A. V. (15 May 2019). "DARK Classics in Chemical Neuroscience: Arecoline". ACS Chemical Neuroscience. 10 (5): 2176–2185. doi:10.1021/acschemneuro.8b00711. PMID30664352. S2CID58554172.
^Liu Naishan, Li Jingjie, & Liu Cuizhen, CN 105439941 2016 to QINGDAO KANGYUAN PHARMACEUTICAL CO Ltd).
^Kozello, I. A.; Khmelevskii, V. I.; Gasheva, A. Ya.; Birbaeva, G. N. (1979). "An improved method of preparation of arecoline, starting from acetaldehyde (exchange of experience)". Pharmaceutical Chemistry Journal. 13 (11): 1158–1159. doi:10.1007/BF00778093.
N
Y (what is this?) (verify)
